278 related articles for article (PubMed ID: 21551235)
1. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.
Kim JH; Choi DS; Lee OH; Oh SH; Lippman SM; Lee HY
Blood; 2011 Sep; 118(9):2622-31. PubMed ID: 21551235
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Oh SH; Kim WY; Lee OH; Kang JH; Woo JK; Kim JH; Glisson B; Lee HY
Cancer Sci; 2012 Jul; 103(7):1259-66. PubMed ID: 22494072
[TBL] [Abstract][Full Text] [Related]
3. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Oh SH; Kim WY; Kim JH; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK; Lee HY
Clin Cancer Res; 2006 Jan; 12(2):653-61. PubMed ID: 16428512
[TBL] [Abstract][Full Text] [Related]
4. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.
Aftab BT; Dobromilskaya I; Liu JO; Rudin CM
Cancer Res; 2011 Nov; 71(21):6764-72. PubMed ID: 21896639
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
Jin Q; Lee HJ; Min HY; Smith JK; Hwang SJ; Whang YM; Kim WY; Kim YH; Lee HY
Carcinogenesis; 2014 Oct; 35(10):2232-43. PubMed ID: 24942865
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β4 expression.
Lee HJ; Lee JS; Hwang SJ; Lee HY
Oncotarget; 2015 Jun; 6(17):15150-63. PubMed ID: 25945837
[TBL] [Abstract][Full Text] [Related]
8. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
9. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Oh SH; Lee OH; Schroeder CP; Oh YW; Ke S; Cha HJ; Park RW; Onn A; Herbst RS; Li C; Lee HY
Mol Cancer Ther; 2006 Nov; 5(11):2685-95. PubMed ID: 17121915
[TBL] [Abstract][Full Text] [Related]
10. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer.
Wang B; Yu W; Guo J; Jiang X; Lu W; Liu M; Pang X
J Pharmacol Exp Ther; 2015 Jan; 352(1):129-38. PubMed ID: 25352499
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells.
Moon Y; Yang H; Kim YB
Toxicol Appl Pharmacol; 2007 Sep; 223(2):155-63. PubMed ID: 17599376
[TBL] [Abstract][Full Text] [Related]
12. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
13. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.
Nishizaki M; Fujiwara T; Tanida T; Hizuta A; Nishimori H; Tokino T; Nakamura Y; Bouvet M; Roth JA; Tanaka N
Clin Cancer Res; 1999 May; 5(5):1015-23. PubMed ID: 10353734
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
Oh SH; Whang YM; Min HY; Han SH; Kang JH; Song KH; Glisson BS; Kim YH; Lee HY
Int J Cancer; 2012 Nov; 131(10):2253-63. PubMed ID: 22362554
[TBL] [Abstract][Full Text] [Related]
15. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells by controlling bFGF and PDGF autocrine/paracrine loops.
Ma Y; Han CC; Li Y; Wang Y; Wei W
Biochem Biophys Res Commun; 2016 Sep; 478(2):964-9. PubMed ID: 27521890
[TBL] [Abstract][Full Text] [Related]
17. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM
Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000
[TBL] [Abstract][Full Text] [Related]
19. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
20. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
